Barclays PLC Has $226,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE)

Barclays PLC grew its holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) by 36.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,889 shares of the company’s stock after purchasing an additional 15,551 shares during the quarter. Barclays PLC owned about 0.19% of Skye Bioscience worth $226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new position in Skye Bioscience during the 2nd quarter worth approximately $30,000. Point72 DIFC Ltd acquired a new position in Skye Bioscience during the 2nd quarter worth approximately $48,000. Jane Street Group LLC acquired a new position in Skye Bioscience during the 3rd quarter worth approximately $48,000. Geode Capital Management LLC raised its stake in Skye Bioscience by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 385,793 shares of the company’s stock worth $1,509,000 after buying an additional 15,614 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Skye Bioscience by 71.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,417 shares of the company’s stock worth $185,000 after buying an additional 19,704 shares during the period. 21.09% of the stock is owned by institutional investors and hedge funds.

Skye Bioscience Trading Up 1.5 %

SKYE stock opened at $2.70 on Wednesday. The firm has a 50 day moving average price of $2.78 and a 200-day moving average price of $3.93. Skye Bioscience, Inc. has a 52-week low of $2.25 and a 52-week high of $19.41.

Insider Buying and Selling at Skye Bioscience

In other Skye Bioscience news, CFO Kaitlyn Arsenault sold 43,206 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.99, for a total transaction of $215,597.94. Following the completion of the sale, the chief financial officer now directly owns 166,342 shares in the company, valued at approximately $830,046.58. The trade was a 20.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tuan Tu Diep sold 19,489 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.99, for a total transaction of $97,250.11. Following the sale, the insider now directly owns 82,259 shares of the company’s stock, valued at approximately $410,472.41. The trade was a 19.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 232,431 shares of company stock worth $1,160,360. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

Separately, Scotiabank assumed coverage on Skye Bioscience in a research note on Monday, September 30th. They issued a “sector outperform” rating and a $20.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $18.67.

Skye Bioscience Profile

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.